Instil Bio (TIL)
(Real Time Quote from BATS)
$10.38 USD
-0.22 (-2.08%)
Updated Apr 29, 2024 12:20 PM ET
2-Buy of 5 2
C Value A Growth B Momentum B VGM
Balance Sheet
Fiscal Year End for Instil Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 152 | 261 | 454 | 242 | 9 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 8 | 10 | 4 | 0 |
Total Current Assets | 161 | 269 | 464 | 246 | 9 |
Net Property & Equipment | 139 | 197 | 122 | 55 | 0 |
Investments & Advances | 23 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 16 | 16 | 0 |
Deposits & Other Assets | 1 | 3 | 8 | 2 | 0 |
Total Assets | 326 | 482 | 610 | 319 | 9 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 6 | 4 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 30 | 34 | 8 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 1 | 1 | 0 |
Total Current Liabilities | 11 | 33 | 41 | 13 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 2 | 2 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 81 | 72 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 8 | 11 | 11 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 332 | 15 |
Total Liabilities | 100 | 119 | 55 | 359 | 16 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 807 | 789 | 757 | 6 | 0 |
Retained Earnings | -581 | -425 | -202 | -45 | -7 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 226 | 364 | 555 | -40 | -7 |
Total Liabilities & Shareholder's Equity | 326 | 482 | 610 | 319 | 9 |
Total Common Equity | 226 | 364 | 555 | -40 | -7 |
Shares Outstanding | 6.50 | 6.40 | 6.40 | NA | NA |
Book Value Per Share | 34.74 | 56.81 | 86.75 | 0.00 | 0.00 |
Fiscal Year End for Instil Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 152 | 183 | 202 | 223 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 9 | 12 | 19 | 17 |
Total Current Assets | NA | 161 | 196 | 221 | 240 |
Net Property & Equipment | NA | 139 | 139 | 181 | 180 |
Investments & Advances | NA | 23 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 3 | 3 | 4 |
Total Assets | NA | 326 | 340 | 408 | 427 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 2 | 2 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 9 | 12 | 16 | 25 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 11 | 13 | 18 | 27 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 81 | 81 | 82 | 77 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 8 | 8 | 8 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 100 | 106 | 112 | 116 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 807 | 803 | 798 | 794 |
Retained Earnings | NA | -581 | -568 | -501 | -482 |
Other Equity | NA | 0 | -1 | -1 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 226 | 234 | 297 | 311 |
Total Liabilities & Shareholder's Equity | NA | 326 | 340 | 408 | 427 |
Total Common Equity | 0 | 226 | 234 | 297 | 311 |
Shares Outstanding | 6.50 | 6.50 | 6.50 | 6.50 | 6.50 |
Book Value Per Share | 0.00 | 34.74 | 36.00 | 45.62 | 47.87 |